MA39908A - Composition médicinale comprenant un composé pyrazine carboxamide utilisé comme principe actif - Google Patents

Composition médicinale comprenant un composé pyrazine carboxamide utilisé comme principe actif

Info

Publication number
MA39908A
MA39908A MA039908A MA39908A MA39908A MA 39908 A MA39908 A MA 39908A MA 039908 A MA039908 A MA 039908A MA 39908 A MA39908 A MA 39908A MA 39908 A MA39908 A MA 39908A
Authority
MA
Morocco
Prior art keywords
inhibiting effect
cancers
jak3
itk
btk
Prior art date
Application number
MA039908A
Other languages
English (en)
Inventor
Satoshi Konagai
Hideki Sakagami
Hiroaki Tanaka
Hiroko Yamamoto
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MA39908A publication Critical patent/MA39908A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le problème décrit par la présente invention est de fournir une composition médicinale destinée à traiter un cancer dans lequel participe au moins une kinase choisie parmi la btk, la jak3 et l'itk. Suite aux résultats d'études sur des composés ayant un effet inhibiteur sur la btk, un effet inhibiteur sur la jak3 et un effet inhibiteur sur l'itk, les présents inventeurs ont confirmé que des composés pyrazine carboxamide spécifiques présentent un effet inhibiteur sur la btk, un effet inhibiteur sur la jak3 et un effet inhibiteur sur l'itk, et que des compositions médicinales comprenant ces composés utilisés comme principe actif présentent un effet thérapeutique sur des cancers dans lesquels participe au moins une kinase choisie parmi la btk, la jak3 et l'itk, des cancers dans lesquels la btk est surexprimée ou activée dans un autre mode de réalisation, des cancers dans lesquels sont activés des signaux de récepteurs de lymphocytes b dans encore un autre mode de réalisation, des cancers dans lesquels la jak3 a subi une mutation-activation dans encore un autre mode de réalisation, et des cancers dans lesquels l'itk est activée dans encore un autre mode de réalisation, achevant ainsi la présente invention.
MA039908A 2014-05-28 2015-05-27 Composition médicinale comprenant un composé pyrazine carboxamide utilisé comme principe actif MA39908A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014109952 2014-05-28

Publications (1)

Publication Number Publication Date
MA39908A true MA39908A (fr) 2015-12-03

Family

ID=54698952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039908A MA39908A (fr) 2014-05-28 2015-05-27 Composition médicinale comprenant un composé pyrazine carboxamide utilisé comme principe actif

Country Status (15)

Country Link
US (1) US20170196859A1 (fr)
EP (1) EP3150206A1 (fr)
JP (1) JPWO2015182628A1 (fr)
KR (1) KR20170005820A (fr)
CN (1) CN106456636A (fr)
AU (1) AU2015266552A1 (fr)
CA (1) CA2949028A1 (fr)
EA (1) EA201692479A1 (fr)
IL (1) IL249010A0 (fr)
MA (1) MA39908A (fr)
MX (1) MX2016015551A (fr)
PH (1) PH12016502313A1 (fr)
SG (1) SG11201609837WA (fr)
TW (1) TW201625254A (fr)
WO (1) WO2015182628A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017013788A (es) 2015-04-27 2018-03-27 Astellas Pharma Inc Composicion farmaceutica estabilizada.
JP2019014653A (ja) * 2015-11-27 2019-01-31 アステラス製薬株式会社 がん免疫を介したがん治療方法
EP3533448A4 (fr) * 2016-10-26 2020-06-10 Astellas Pharma Inc. Composition pharmaceutique stable
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201510696RA (en) * 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
CN102947316B (zh) * 2010-06-23 2016-08-10 韩美科学株式会社 用于抑制酪氨酸激酶活性的新型稠合嘧啶衍生物
AU2013210438B2 (en) * 2012-01-17 2016-11-10 Astellas Pharma Inc. Pyrazine carboxamide compound

Also Published As

Publication number Publication date
EP3150206A1 (fr) 2017-04-05
WO2015182628A1 (fr) 2015-12-03
TW201625254A (zh) 2016-07-16
PH12016502313A1 (en) 2017-02-13
JPWO2015182628A1 (ja) 2017-04-20
US20170196859A1 (en) 2017-07-13
CA2949028A1 (fr) 2015-12-03
MX2016015551A (es) 2017-03-23
CN106456636A (zh) 2017-02-22
KR20170005820A (ko) 2017-01-16
AU2015266552A1 (en) 2016-12-01
SG11201609837WA (en) 2016-12-29
IL249010A0 (en) 2017-01-31
EA201692479A1 (ru) 2017-03-31

Similar Documents

Publication Publication Date Title
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
PH12016501578A1 (en) Pharmaceutical compounds
PH12020550901A1 (en) Macrocyclic compounds for treating disease
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12016501963B1 (en) Macrocyclic pyrimidine derivatives
PH12016501962B1 (en) Macrocyclic pyridine derivatives
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
PH12016501527B1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
PT3279210T (pt) Péptido com atividade anticancerígena, composição farmacêutica e composição de suplementos alimentares para prevenção e tratamento do cancro, ambos os quais contêm o mesmo ingrediente ativo
PH12016502313A1 (en) Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
PH12017501334B1 (en) 3,5-diaminopyrazole kinase inhibitors
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
MX2017007648A (es) Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo.